How much did the US market gain over the past year?

The US market rose 26% over the past year.

What is the expected earnings growth for companies?

Earnings are forecast to grow by 17% annually.

Is this a buy recommendation?

No, the analysis provides estimates only and is not a buy recommendation. Further research is advised.

3 Stocks Estimated 16-42% Below Intrinsic Value: ABBV, MRK

Despite a flat week, the US market is up 26% over the past year with 17% annual earnings growth expected. Simply Wall St. identifies AbbVie (ABBV) and Merck (MRK) as trading below intrinsic value by 16.4% to 42%.

June 4, 2026

2 min read

Source: Simply Wall St.

Key Numbers

market return 1y

26%

earnings growth forecast

17%

discount abbv

42%

discount mrk

16.4%

The US market remained flat last week but has gained 26% over the past year, with earnings forecast to grow 17% annually. In this robust environment, Simply Wall St. highlights three stocks estimated to trade below their intrinsic value, including AbbVie (ABBV) and Merck (MRK).

Details

According to the analysis, AbbVie (ABBV) trades at a discount of up to 42% to its intrinsic value, while Merck (MRK) is 16.4% below. The valuation is based on discounted cash flow models and growth assumptions.

Context

The strong US market performance over the past year has been driven by earnings growth expectations. However, some healthcare stocks like AbbVie and Merck remain undervalued according to this analysis.

What This Means for Investors

These estimates are not a buy recommendation but indicate potential opportunities for investors seeking undervalued stocks. Further due diligence on each company's fundamentals is advised before making investment decisions.

Frequently Asked Questions

According to Simply Wall St., AbbVie (ABBV) and Merck (MRK) are among stocks trading at discounts of up to 42% and 16.4%, respectively.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.